Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and 2007
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) today reported financial results for the fourth quarter and twelve months ended December 31, 2007 and revised 2008 earnings guidance primarily to reflect the sale of the Medical Imaging business.
Nycomed and Wyeth announce launch of an own generic version of PROTONIX®
- Details
- Category: Nycomed
Nycomed and its licence holder Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), today announced the U.S. launch of an own generic version of PROTONIX® (Pantoprazole) tablets, in response to the at-risk launch of generic Pantoprazole tablets by Teva Pharmaceuticals USA, Inc. Today's launch terminates the current standstill agreement between Nycomed, Wyeth and Teva.
TransTech Pharma, Inc. Acquires Three Programs from Novo Nordisk
- Details
- Category: Novo Nordisk
Novo Nordisk A/S announced that TransTech has acquired all rights from Novo Nordisk to a portfolio of drug candidates being developed to treat metabolic disorders. This portfolio is comprised of three distinct therapeutic approaches to such treatment: H3 receptor antagonists, PPARδ agonists and 11βHSD1 inhibitors.
Pfizer Reports Fourth-Quarter and Full-Year 2007 Results
- Details
- Category: Pfizer
Pfizer Inc (NYSE: PFE) reported results for the fourth-quarter and full-year 2007. For the fourth-quarter 2007, Pfizer recorded revenues of $13.1 billion, an increase of 4% compared with $12.6 billion in the year-ago quarter, despite the March 2007 loss of U.S. exclusivity of Norvasc, which contributed to a decrease in Norvasc revenues of $667 million.
Teva to acquire CoGenesys with a purchase price of $400 million cash
- Details
- Category: Financial
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced that it has entered into a definitive agreement to acquire CoGenesys, Inc., a privately-held biopharmaceutical company with a broad based biotechnology platform and focused on the development of peptide- and protein-based medicines across broad therapeutic categories.
Abbott Reports 16.1 Percent Sales Growth in Fourth Quarter
- Details
- Category: Abbott
Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2007.
- Worldwide sales in the fourth quarter increased 16.1 percent to $7.2 billion, including a favorable 4.5 percent effect of exchange rates. For the full-year 2007, worldwide sales increased 15.3 percent to $25.9 billion, including a favorable 3.2 percent effect of exchange rates.
ANAVEX outlines corporate milestones, drug advancement plans for 2008
- Details
- Category: Business
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) reported that the company achieved significant development of its lead drug candidates and in the growth of its management and scientific teams during 2007. The company further disclosed key corporate objectives for 2008.
More Pharma News ...
- Roche invests 430 million Swiss francs at sites in Germany and Switzerland
- Novartis achieves record results in 2007 underscoring benefits of strategic healthcare portfolio
- Pfizer and Scil Finalize Agreement for Novel Cartilage Growth Factor
- First Head to Head Study Comparing CRESTOR and LIPITOR®
- Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R)
- Pfizer Wins Key New York State Court Ruling on Celebrex
- Roche engages in four additional AIDS Technology Transfers